文献速递湿疹皮炎与荨麻疹药疹与重症皮肤不良反应

男性面部皮炎斑贴试验特征:NACDG 1994-2016回顾分析

Facial Dermatitis in Male Patients Referred for Patch Testing: Retrospective Analysis of North American Contact Dermatitis Group Data, 1994 to 2016.
PubMed 文献 · JAMA Dermatol · 2020-01-01

男性面部皮炎患者较无面部皮炎者更年轻,对二甲氨基丙胺和對苯二胺的反应风险更高,主要致敏源多来自个人护理产品。

要点

  • 男性面部皮炎常见部位为面部(非特指)、眼睑和唇部。
  • 男性面部皮炎患者更年轻,更少为白人,职业相关皮肤病比例更低。
  • 常见临床相关变应原包括甲基异噻唑啉酮、香料混合物I和秘鲁香脂。

核心结论

  • 男性面部皮炎患者对二甲氨基丙胺和對苯二胺的斑贴试验反应风险高于无面部皮炎男性,推测与美发产品使用较多有关。
  • 男性面部皮炎中多数变应性和刺激性接触性皮炎来源为个人护理产品。

研究设计与样本

  • 面部皮炎定义为累及眼、眼睑、唇、鼻或面部(非特指)。

主要发现

  • MFD组平均(SD)年龄47(17.2)岁,MNoFD组50(17.6)岁,MFD组显著更年轻(P < .001)。
  • 最常见面部部位为面部非特指(817例,48.9%)、眼睑(392例,23.5%)、唇(210例,12.6%)。
  • MFD组较MNoFD组更少为白人(RR 0.92;95% CI -0.90至0.95),更少患职业相关皮肤病(RR 0.49;95% CI -0.42至0.58;P < .001)。
  • MFD组常见临床相关变应原包括甲基异噻唑啉酮(n=113;9.9%)、香料混合物I(n=27;8.5%)、秘鲁香脂(n=90;6.8%)。
  • MFD组较MNoFD组更易对二甲氨基丙胺(RR 2.49;95% CI -1.42至4.37)和對苯二胺(RR 1.43;95% CI -1.00至2.04;P < .001)反应。

关键数值与推荐

  • MFD组与MNoFD组平均年龄47岁 vs 50岁(P < .001)。
  • 白人相对风险RR 0.92(95% CI -0.90至0.95)。
  • 职业相关皮肤病相对风险RR 0.49(95% CI -0.42至0.58;P < .001)。
  • 二甲氨基丙胺相对风险RR 2.49(95% CI -1.42至4.37);對苯二胺相对风险RR 1.43(95% CI -1.00至2.04;P < .001)。

临床怎么用

  • 临床遇男性面部皮炎患者应考虑斑贴试验,尤其怀疑美发产品或个人护理产品暴露时。
  • 关注甲基异噻唑啉酮、香料混合物I、秘鲁香脂、二甲氨基丙胺和對苯二胺等变应原。
  • 详细询问个人护理产品使用史,以识别潜在致敏来源。

局限性

  • 回顾性横断面设计,可能存在选择偏倚和信息偏倚。
  • 数据来自NACDG多中心转诊人群,结果外推需谨慎。
  • 部分变应原亚组样本量较小,相对风险置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Facial dermatitis in women is well characterized. However, recent shifts in the men's grooming industry may have important implications for male facial dermatitis. OBJECTIVE: To characterize male patients with facial dermatitis. DESIGN, SETTING, AND PARTICIPANTS: A 22-year retrospective cross-sectional analysis (1994-2016) of North American Contact Dermatitis Group (NACDG) data, including 50 507 patients who underwent patch testing by a group of dermatology board-certified patch test experts at multiple centers was carried out. Facial dermatitis was defined as involvement of the eyes, eyelids, lips, nose, or face (not otherwise specified). MAIN OUTCOMES AND MEASURES: The main outcome was to compare characteristics (including demographics and allergens) between male patients with facial dermatitis (MFD) and those without facial dermatitis (MNoFD) using statistical analysis (relative risk, CIs). Secondary outcomes included sources of allergic and irritant contact dermatitis and, for occupationally related cases, specific occupations and industries in MFD. RESULTS: Overall, 1332 male patients (8.0%) were included in the MFD group and 13 732 male patients (82.0%) were included in MNoFD. The mean (SD) age of participants was 47 (17.2) years in the MFD group and 50 (17.6) years in the MNoFD group. The most common facial sites were face (not otherwise specified, 817 [48.9%]), eyelids (392 [23.5%]), and lips (210 [12.6%]). Participants in the MFD group were significantly younger than MNoFD (mean age, 47 vs 50 years; P < .001). Those in the MFD group were less likely to be white (relative risk [RR], 0.92; 95% CI, -0.90 to 0.95) or have occupationally related skin disease (RR, 0.49; 95% CI, -0.42 to 0.58; P < .001) than MNoFD. The most common allergens that were associated with clinically relevant reactions among MFD included methylisothiazolinone (n = 113; 9.9%), fragrance mix I (n = 27; 8.5%), and balsam of Peru (n = 90; 6.8%). Compared with MNoFD, MFD were more likely to react to use of dimethylaminopropylamine (RR, 2.49; 95% CI, -1.42 to 4.37]) and paraphenylenediamine (RR, 1.43; 95% CI, -1.00 to 2.04; P < .001). Overall, 60.5% of NACDG allergen sources were personal care products. CONCLUSIONS AND RELEVANCE: Although many allergens were similar in both groups, MFD were more likely to react to use of dimethylaminopropylamine and paraphenylenediamine, presumably owing to their higher prevalence in hair products. Most sources of allergic and irritant contact dermatitis in MFD were personal care products. This study provides insight into the risks and exposures of the increasing number of grooming products used by male dermatology patients. This will enable clinicians to better identify male patients who would benefit from patch testing and treat those with facial dermatitis.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Warshaw EM, Schlarbaum JP, Maibach HI, et al. Facial Dermatitis in Male Patients Referred for Patch Testing: Retrospective Analysis of North American Contact Dermatitis Group Data, 1994 to 2016. JAMA Dermatol. 2020. PMID: 31774459. doi:10.1001/jamadermatol.2019.3531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。